Information for patients
We work with cancer patients to provide a range of personalised tests so you can choose the best treatment.
More patient informationThis site uses cookies: find out more.
We work with cancer patients to provide a range of personalised tests so you can choose the best treatment.
More patient informationFind answers to some of your most frequently asked questions
New methods and reliable tests to help deliver personalised treatment
RGCC CAMBISeq® is an innovative test that uses next-generation sequencing analysis on both DNA and RNA to provide clinicians with a crucial insight into cancer. The CAMBISeq® – or cancer analysis, mutational burden and instability sequencing – test is used to identify variants in 500 genes that our scientists use as biomarkers to assess their […]
The array comparative genomic hybridisation (aCGH) RGCC test is used to identify chromosomal abnormalities in a patient that could lead to cancer. During the test, scientists use a technique called array comparative genomic hybridisation to spot abnormalities in a genome. This insight enables them to assess the likely risk of cancer developing and the potential […]
Immune-Frame is used to assess the condition of a patient’s immune system. Scientists use the test to identify specific cellular markers that are responsible for switching a patient’s immune system on and off. The results of Immune-Frame can be used to analyse the status of a patient’s immune system, and to provide ongoing information about […]
Metastat RGCC is an advanced test to detect specific blood-borne markers that can accurately determine whether a secondary cancerous tumour is likely to develop and its potential location. During the test, we analyse a sample of a patient’s blood in our state-of-the-art laboratory to analyse, identify and measure circulating tumour cells (CTCs). Metastat RGCC is […]
ChemoSNiP is an innovative test that uses an advanced scientific technique called pharmacogenomics to analyse how a patient’s body will respond to a specific drug. ChemoSNiP analyses a blood sample to identify for single nucleotide polymorphisms – variations in our DNA sequence that can affect if we develop cancer or if we respond to treatments […]
Onconomics Extracts is a unique and highly detailed test that provides information on how effective natural substances and plants extracts are at attacking circulating cancer cells (CTCs). Onconomics Extracts uses three unique and scientifically-proven methods to assess how effective natural treatments are at tackling cancer. The results provide a comprehensive and highly personalised analysis of […]
Onconomics Plus RGCC provides information about the effect of specific anti-cancer drugs, targeted therapies and natural treatments on the cancer cells in an individual patient. During the test, a sample of blood or tissue is analysed to test how effective specific therapies and treatments are at suppressing cancer. Together, the results of the extensive tests […]
Onconomics RGCC provides highly detailed and accurate information about how effective specific anti-cancer drugs and targeted therapies are in treating cancer. The test combines a molecular and a cellular approach by incorporating two procedures: epigenetic analysis and viability assays. A sample of blood or tissue is analysed to test how effective specific therapies and treatments […]
Oncotrail RGCC provides crucial information on the presence of circulating tumour cells (CTCs) and their concentration in patients who have a confirmed diagnosis of specific forms of cancer, including breast, colon and prostate cancer. During the test, a sample of blood is analysed to identify the presence and concentration of CTC and their immunophenotype. Oncotrail […]
Oncotrace RGCC is used to identify a primary tumour in a patient and to provide guidance about disease progression and future prognosis. During the test, a sample of blood is analysed to identify the presence and concentration of circulating tumour cells (CTCs) and their concentration. This test provides information about the presence of CTCs, their […]
Oncocount RGCC detects the presence of circulating tumour cells (CTCs) and their concentration in the blood. CTCs are a powerful biomarker, and their presence in the blood can act as an early warning sign that cancer is returning. The test is designed as a follow-up test for patients who have cancer and are worried about […]
Use our ‘smart filter’ to identify which test is best for your patients
Find out moreFind out more about our latest research, trials and education days
RGCC researchers have developed a new approach to tackling COVID-19 (SARS-CoV-2) that could form the basis of a new treatment option. Laboratory tests have established that the new treatments were effective at inhibiting the spread of the disease. The next stage will see them progress to develop a drug delivery system, a further step before […]
A new cancer vaccine is 75% effective at eliminating cancerous tumours in mice, say scientists at the University of Konstanz. The combination treatment includes a powerful immunostimulant and a targeted immunotherapy called a cancer checkpoint inhibitor in one dose. Described by the team as a “potent cancer vaccine”, the combination therapy is already being tested […]
US scientists have developed the world’s first ‘tumour-uninformed’ test that can detect cancer DNA circulating in the blood of cancer patients following treatment. The liquid biopsy test enables clinicians to test for cancer without needing a sample of tumour tissue. It’s an exciting development and adds yet more evidence to the potential for liquid biopsies […]
RGCC scientists have developed a new anti-cancer dietary supplement that’s 34% more effective than the leading brand. Led by RGCC’s Dr Ioannis Papasotiriou, the new product offers yet more evidence of the potential for dietary supplements in the battle against cancer. It also demonstrates RGCC’s cutting-edge research and discovery capabilities. Genistein is a naturally occurring […]
Researchers have developed an effective vaccine that re-engineers cells from a patient’s tumour to target and destroy cancer cells. The results, published in the peer-reviewed Journal of Clinical Oncology, show that 45% of patients treated with an autologous cell vaccine, created from their own cancer cells, had a confirmed anti-tumour response. The findings provide more […]
No, due to the blood-brain barrier, tumour cells cannot enter the bloodstream. This means that we cannot obtain and isolate any tumour cells from the blood sample.
Yes, patients with lymphoma or leukaemia can use an RGCC test to measure the number of circulating tumour cells (CTC) they have.
The most comprehensive test is the “Onconomics Plus” test. This provides information on the sensitivity or resistance of the patient’s tumour cells to certain cancer drugs and shows options for targeted therapy or an alternative treatment method with organic substances. The test also contains information about the development of the tumour and its potential by identifying epigenetic tumour markers relevant for the therapy, which are crucial for the correct therapeutic approach.
Online consultations will give you the opportunity to speak to any member of the RGCC Network at a time and place that is convenient to you. You will be able to choose from a shortlist of clinicians who best suit your needs. The online consultation will be available via the Cancer A-Z app soon… please keep checking the app for updates.
Your chosen clinician will be in touch to make the arrangements and choose the most convenient method.
Didn't find an answer to your question? Contact us directly.
Get in touchRGCC operates in 23 countries across the world, with bases in all five continents.
Find out more